1-((phenyl)(1-methylpiperidin-4-yl)methyl)piperazine | 878162-22-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 1-((phenyl)(1-methylpiperidin-4-yl)methyl)piperazine
• 英文别名: 1-[(1-methylpiperidin-4-yl)-phenylmethyl]piperazine
• CAS: 878162-22-2
• 化学式: C₁₇H₂₇N₃
• 分子量: 273.421
• InChiKey: PKMTZYIGQYLXOJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  20
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.65
• 拓扑面积：
  18.5
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-((phenyl)(1-methylpiperidin-4-yl)methyl)piperazine 、 3,3-二苯基丙酸 在 4-二甲氨基吡啶 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下， 以 二氯甲烷 为溶剂， 生成 1-[4-[(1-Methylpiperidin-4-yl)-phenylmethyl]piperazin-1-yl]-3,3-diphenylpropan-1-one
  参考文献：
  名称：

  Structure–activity relationships of diphenylpiperazine N-type calcium channel inhibitors

  摘要：

  A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.008
• 作为产物：
  描述：

  tert-butyl 4-((1-methylpiperidin-4-yl)(phenyl)methyl)piperazine-1-carboxylate 在 三氟乙酸 作用下， 以 二氯甲烷 为溶剂， 生成 1-((phenyl)(1-methylpiperidin-4-yl)methyl)piperazine
  参考文献：
  名称：

  Structure–activity relationships of diphenylpiperazine N-type calcium channel inhibitors

  摘要：

  A novel series of compounds derived from the previously reported N-type calcium channel blocker NP118809 (1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one) is described. Extensive SAR studies resulted in compounds with IC50 values in the range of 10-150 nM and selectivity over the L-type channels up to nearly 1200-fold. Orally administered compounds 5 and 21 exhibited both anti-allodynic and anti-hyperalgesic activity in the spinal nerve ligation model of neuropathic pain. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.01.008

文献信息

• Urea derivatives as calcium channel blockers
  申请人：Pajouhesh Hassan

  公开号：US20060063775A1

  公开（公告）日：2006-03-23

  Urea derivatives which comprise piperidine or piperazine rings and further substitution are effective in ameliorating conditions characterized by unwanted calcium ion channel activity.

  含有哌啶或哌嗪环及其进一步取代的尿素衍生物，在改善由不良钙离子通道活性所表征的状况方面效果显著。
• UREA DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
  申请人：Pajouhesh Hassan

  公开号：US20080207633A1

  公开（公告）日：2008-08-28

  Urea derivatives which comprise piperidine or piperazine rings and further substitution are effective in ameliorating conditions characterized by unwanted calcium ion channel activity.

  含有哌啶或哌嗪环且进一步置换的尿素衍生物对于改善由于不必要的钙离子通道活性所表现出的情况是有效的。
• HETEROCYCLIC AMIDE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS
  申请人：Pajouhesh Hassan

  公开号：US20090221603A1

  公开（公告）日：2009-09-03

  Methods and compounds effective in ameliorating conditions characterized by unwanted calcium channel activity, particularly unwanted N-type or T-type calcium channel activity are disclosed. Specifically, a series of heterocyclic amides are disclosed of the general formula (1) where Z is N or ═CHNR 2 and X is NR 2 , O, S, S═O or SO 2 . Among other definitions for R, R 1 , W and Y, the compounds of formula (1) are further characterized by at least one of W or Y being CR 3 Ar 2 where Ar is an aromatic or heteroaromatic ring (for example, where W or Y is a benzhydryl moiety).

  公开了对缓解由不需要的钙通道活性，特别是不需要的N型或T型钙通道活性所表征的情况有效的方法和化合物。具体而言，公开了一系列杂环酰胺，其通式为（1），其中Z为N或═CHNR2，X为NR2、O、S、S═O或SO2。在R、R1、W和Y的其他定义中，式（1）化合物进一步表征为至少有一个W或Y为CR3Ar2，其中Ar为芳香或杂芳环（例如，当W或Y为苯甲基基团时）。
• WO2007/71035
  申请人：——

  公开号：——

  公开（公告）日：——
• EP1784401A4
  申请人：——

  公开号：EP1784401A4

  公开（公告）日：2009-07-15